Sevenfact market to grow on hemophilia demand and safer clotting therapies

The Sevenfact market is expanding as hemophilia care shifts toward personalized treatment, safer recombinant products and home-based bleeding management. The Business Research Company says North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Sevenfact is used to control bleeding in patients with hemophilia A or B who have inhibitors, a group that needs specialized treatment options. - Growth in blood disorders and broader use of targeted hemophilia therapies are widening demand for recombinant coagulation products. - Rising healthcare spending could support more adoption of treatments that reduce hospitalizations and emergency care.

What happened: - The Business Research Company published its Sevenfact Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Sevenfact market is gaining momentum on the back of treatment advances and growing awareness of blood disorders. - The market is expected to be shaped between 2026 and 2030 by personalized therapies and innovative coagulation agents. - Download a free sample of the sevenfact market report. - View the full sevenfact market report.

The details: - Sevenfact is a recombinant coagulation factor VIIa, also known as eptacog beta. - The drug is designed to treat and control bleeding episodes in patients with hemophilia A or B who have developed inhibitors. - During the historic period, market growth was driven by recombinant clotting factor technology and better survival rates for people with hemophilia. - Specialized hemophilia treatment centers, targeted bleeding management protocols and more awareness of inhibitor-related complications also supported demand. - Forecast-period growth is expected to accelerate with wider use of personalized hemophilia treatments and stronger demand for safer recombinant products. - Other drivers include more home-based bleeding management options, greater use of prophylactic treatment and next-generation coagulation agents. - Key trends include more recombinant coagulation factor use, improved inhibitor hemophilia management, stronger demand for on-demand bleeding control therapies, precision hemostasis treatments and rapid-acting clotting agents. - Blood disorders affect red and white blood cells, platelets and plasma. - The report links demand to aging populations, genetic predispositions, chronic illnesses, infections and inflammatory conditions. - A CDC report released in April 2024 cited 2.8 million physician office visits for anemia as a primary diagnosis and 6,021 deaths, equal to 1.8 deaths per 100,000 people. - In November 2023, the Canadian Institute for Health Information projected total health expenditure in Canada would reach $344 billion in 2023, up 2.8% from the previous year. - North America held the largest share of the Sevenfact market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and future-trend analysis.

Between the lines: - The report points to a market moving from niche hospital use toward broader, more flexible care settings. - Demand appears tied not just to disease burden, but to products that can simplify bleeding control and fit into preventive treatment plans. - Regional growth expectations suggest the commercial center of gravity may shift beyond North America as hemophilia care expands in faster-growing markets.

What's next: - The market outlook through 2030 will likely depend on how quickly personalized hemophilia care and safer recombinant therapies gain adoption. - More competition may emerge around rapid-acting, on-demand bleeding control products and home-use treatment models. - The Business Research Company is positioning its updated report tools around scenario planning and market hotspot identification for buyers and investors.